MedPath

The effect and safety of the drug Acyclovir in patients of Pityriasis rosea (a widespread red and scaly lesion following infection or drug intake)

Phase 4
Conditions
Health Condition 1: null- Patients suffering from Pityriasis rosea
Registration Number
CTRI/2013/12/004240
Lead Sponsor
Institutional Medical College Kolkata
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
24
Inclusion Criteria

a.All patients presenting with pityriasis rosea.

b.Patients giving informed written consent

Exclusion Criteria

a.Patients not willing to participate in the study

b.Pregnant or breast feeding women

c.Any history of sensitivity to acyclovir or erythromycin or cetirizine

d.Renal or hepatic impairment

e.Suspicion of having fungal infection, psoriasis, or eczema.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of symptoms (Symptom score) on a 0-10 scaleTimepoint: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks following randomoization
Secondary Outcome Measures
NameTimeMethod
1. Spontaneously reported adverse events <br/ ><br>2. Adverse events elicited by the clinicians <br/ ><br>Timepoint: 1 week, 2 weeks, 3 weeks, 4 weeks following randomoization
© Copyright 2025. All Rights Reserved by MedPath